Protocol Of Neurological Indications To Percutaneous Left Atrial Appendage Closure For Stroke Prevention In Atrial Fibrillation

M Masato, C F Salimbeni, S Saccà, M Michieletto, B Reimers, D D’Este, A Bruscagnin, C Bruscagnin

Citation

DOI: 10.5580/IJN.32959

Abstract
Atrial fibrillation is a frequent cardiac arrhythmia. The prevalence is 2-2.7% in middle aged population; it increases with ageing and approaches 8% in elderly people. There is high cardioembolic risk related to atrial fibrillation: about 20% of strokes are caused by this common arrhythmia. The aim of this study is to identify patients with selective clinical features to address to left atrial appendage closure.

INTRODUCTION
Atrial fibrillation is a frequent cardiac arrhythmia. The prevalence is 2-2.7% in middle aged population; it increases with ageing and approaches 8% in elderly people. There is high cardioembolic risk related to atrial fibrillation: about 20% of strokes are caused by this common arrhythmia.

Oral anticoagulation remains the mainstream therapy for ischemic stroke prevention in patients with atrial fibrillation and warfarin therapy is considered the first choice, since it reduces about 60% of strokes. However the anticoagulant therapy has many limitations, such as food interactions, and relative/absolute contraindications due to haemorrhagic complications. Patients often discontinue warfarin for a variety of reasons and chronic warfarin administration rates remains indeed suboptimal. Although the compliance with anticoagulation may improve with new anticoagulants and the bleeding risk can be reduced compared with that of warfarin, there is still a progressive increase in bleeding complications over time.


MATERIALS AND METHODS
The Departments of Neurology and Cardiology of Mirano-Venice Hospital cooperated to analyze neurological patients with Ischemic and Haemorrhagic Strokes and identified in high haemorrhagic risk categories with controidication to anticoagulant therapy.

CHA2DS2Vasc score was used to identified ischemic risk, HAS-BLED score was used to identified haemorrhagic risk, but also other clinical characteristics were considered as haemorrhagic risk as HAS-BLED.

Neuroimaging was the main source, since it can identify site and extension of haemorrhagic lesions, presence of microbleeding and leukoaraiosis.

It was assessed if there is major indication to left atrial appendage between ischemic patients or haemorrhagic patients, keeping in mind that obviously haemorrhagic risk
for ischemic stroke is a systemic risk (internal medicine diseases).

The neurological protocol

a) Evaluation of contrindications for prolonged use of oral anticoagulants (vitamin K antagonist -VKA and new oral anticoagulant -NOA) that we have divided in:

1) ABSOLUTE:
   - atypical cerebral seat haemorrhagia (lobar): amiloidotic angiopathy, vascular malformations and lesional haemorragic cerebral diseases.
   - relapse of haemorrhagic cerebral event

2) RELATIVE:
   - typical cerebral seat cerebral haemorrhagia (deep)
   - systemic internal medicine diseases with haemorrhagic risk

b) Esclusion of other thrombo-embolic causes using Sovra-aortic Eco_Doppler sonography and Echocardiography:
   - Carotic plaques
   - Aortic Arch plaques
   - Cardiac Thrombosis
   - Valvular pathology with thrombosis

c) Examination of Neuroimaging (CT e MRI performed with gradient-echo sequencies too)

d) Haematochemical examinations (for thrombophilic and inflammatory predisposition):

   INR, PT, aPTT, fibrinogen, ATIII

   C protein,. Resistance to Activated C protein, S protein

   Antiphospholipids Ab, beta2 glicoprotein Ab

   Homocysteine

   Mutations in Factor II, Leiden’s Factor V e MTHFR

   ENA, ANA, ANCA, C3-C4, rheumatoid factor

e) Evaluation of limitations for use of new oral anticoagulants (NOA):

   renal insufficiency-failure, hepatic insufficiency-failure, gastroenteric haemorrhagic risk, other haemorrhagic risks

   due to medical problems, cancer with haemorrhagic risk, pharmacological interactions for continuative drug use (carbamazepine e phenytoin with dabigatran, atorvastatin with dabigatran, SSRI e SNRI with dabigatran, NSAIDs)

f) Evaluation of haemorrhagic risk that is not identifiable using HAS-BLED score:

   triple therapy for presence of coronary stents, cancer with haemorrhagic risk, inflammatory bowel diseases (IBDs), compliance of the patients, risk of falls, absence of caregiver for old disabled patients.

g) Decision of the patients: always to be considered.

CLINICAL RECORDS in the period between 2012-2014

27 patients: 18 males, 9 females

Average age: 74 years old (from 54 to 85)

Pathology: Ischemic Stroke: 10, Haemorrhagic Stroke: 10, Other conditions: 7

Typical cerebral haemorrhagia: 4, Atypical cerebral haemorrhagia: 2, Subdural haemorrhagia: 3, Spinal haemorrhagia: 1, AIT: 3, Ischemic Stroke: 7, Other haemorrhagic risk: 7

CONCLUSIONS

It’s necessary to have clear basis before addressing patients to LAA closure and Neuroimaging is very helpful and reliable for this purpose. It’s highly recommended to evaluate limitations in use of NOACs. Patients are selected case to case.

Figure 1
Protocol Of Neurological Indications To Percutaneous Left Atrial Appendage Closure For Stroke Prevention In Atrial Fibrillation

Figure 2

Chart 1
Chart Of Diagnostic Points

- Realisation of contraindication of prolongue use of oral anticoagulant (VPA or NOACs) due to high hemorrhagic risk
- Exclusion of embolic causes different of atrial fibrillation using ultrasonic of supra aortic vessels and transesophageal echocardiography
- Realisation of non managers (CT scan and MRI) and research of microbleeds with MRI (gradient echo)
- Blood tests for thrombophilic conditions
- Identify clinical limitations of use of NOACs
- Realisation of hemorrhagic risk in conditions non included in HAS-BLED score
- Decision of the patient

Chart 2
Flow Chart

References

11. PD Mudd and MA James Anticoagulation for atrial fibrillation: should warfarin be temporarily stopped or continued after acute cardioembolic stroke? Age and Ageing 2010 39: 670-673
15. RP Whitlock, JS Healey, SJ Connolly Left atrial appendage occlusion does not eliminate the need for warfarin Circulation 2009 120: 1927-1932
16. Guidelines:
   - Italian guidelines SPREAD 2012
   - ESC 2012
   - AHA-ASA 2014
   - AHA/ACC/HRS 2014
   - EHR/EPACI expert consensus statement on catheter-based left atrial appendage occlusion. B Meier, Y Blauw, AA Khattab, T Lewalter, H Sievert, C Tondo, M Glikson Europace September 2014
Author Information

Maela Masato
Department of Neurology Mirano-Dolo (Ve)
Venice, Italy

Carlo Fattorello Salimbeni
Department of Neurology Mirano-Dolo (Ve)
Venice, Italy

Salvatore Saccà
Department of Cardiology Mirano (Ve)
Venice, Italy

Marco Michieletto
Department of Cardiology Mirano (Ve)
Venice, Italy

Bernhard Reimers
Department of Cardiology Mirano (Ve)
Venice, Italy

Daniele D’Este
Department of Cardiology Dolo (Ve)
Venice, Italy

Andrea Bruscagnin
Department of Radiology Mirano (Ve)
Venice, Italy

Chiara Bruscagnin
Venice, Italy